Title: 2025-2026 Regular Session HR 182 PN 1280 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN1280
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session HR 182 PN 1280 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1280 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.182 Session of 2025 INTRODUCED BY MALAGARI, HILL-EVANS, FREEMAN, KENYATTA, VENKAT, GIRAL, KHAN, SANCHEZ, SCHLOSSBERG, D. WILLIAMS, O'MARA, CERRATO, GREEN AND CURRY, APRIL 7, 2025 REFERRED TO COMMITTEE ON HEALTH, APRIL 7, 2025 A RESOLUTIONRecognizing the month of June 2025 as "Scleroderma Awareness Month" and June 29, 2025, as "World Scleroderma Day" in Pennsylvania.WHEREAS, Scleroderma is a rare group of autoimmune diseases that makes the skin harden and tighten, which may cause issues in the blood vessels, gastrointestinal tract, heart and lungs; andWHEREAS, There are two main groups of scleroderma, localized scleroderma, which typically only affects one area of the skin, and systemic scleroderma, which affects the skin as well as the internal organs; andWHEREAS, Approximately 300,000 individuals in the United States have scleroderma, with one-third of those individuals having systemic scleroderma; andWHEREAS, Up to 80% of individuals diagnosed with scleroderma are women; andWHEREAS, African Americans are more likely to be diagnosed with systemic scleroderma than non-African Americans, and 123456789101112131415161718 African Americans are also more likely to have earlier onset of the disease and more severe symptoms; andWHEREAS, Scleroderma commonly occurs between 25 and 55 years of age; andWHEREAS, Symptoms commonly affect the face, feet, fingers, and hands first, and early symptoms include hardening and tightening of the skin, swelling and itchiness; andWHEREAS, Diagnosis may include physical exams, laboratory tests for antibodies, skin biopsies, computerized tomography, echocardiograms and pulmonary function tests; andWHEREAS, There is not a cure for scleroderma, but treatment may include medications to dilate blood vessels, suppress the immune system, reduce stomach acid, prevent infections of ulcers caused by Raynaud's phenomenon and alleviate pain, in addition to physical and occupational therapies and stem cell and organ transplants; andWHEREAS, Symptoms associated with scleroderma may decrease on their own in three to six years, while systemic scleroderma, which damages the internal organs, continues to worsen; andWHEREAS, Thomas Jefferson University, the University of Pennsylvania, the University of Pittsburgh and other entities in Pennsylvania continue to research scleroderma, enabling individuals to receive treatment to mitigate their symptoms; andWHEREAS, Awareness of rare diseases such as scleroderma assists in individuals' knowledge about the symptoms, research to treat these rare diseases and providing supports to individuals with rare diseases; therefore be itRESOLVED, That the House of Representatives recognize the month of June 2025 as "Scleroderma Awareness Month" and June 29, 2025, as "World Scleroderma Day" in Pennsylvania.20250HR0182PN1280 - 2 - 123456789101112131415161718192021222324252627282930


================================================================================

Raw Text:
2025-2026 Regular Session HR 182 PN 1280 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1280 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.182 Session of 2025 INTRODUCED BY MALAGARI, HILL-EVANS, FREEMAN, KENYATTA, VENKAT, GIRAL, KHAN, SANCHEZ, SCHLOSSBERG, D. WILLIAMS, O'MARA, CERRATO, GREEN AND CURRY, APRIL 7, 2025 REFERRED TO COMMITTEE ON HEALTH, APRIL 7, 2025 A RESOLUTIONRecognizing the month of June 2025 as "Scleroderma Awareness Month" and June 29, 2025, as "World Scleroderma Day" in Pennsylvania.WHEREAS, Scleroderma is a rare group of autoimmune diseases that makes the skin harden and tighten, which may cause issues in the blood vessels, gastrointestinal tract, heart and lungs; andWHEREAS, There are two main groups of scleroderma, localized scleroderma, which typically only affects one area of the skin, and systemic scleroderma, which affects the skin as well as the internal organs; andWHEREAS, Approximately 300,000 individuals in the United States have scleroderma, with one-third of those individuals having systemic scleroderma; andWHEREAS, Up to 80% of individuals diagnosed with scleroderma are women; andWHEREAS, African Americans are more likely to be diagnosed with systemic scleroderma than non-African Americans, and 123456789101112131415161718 African Americans are also more likely to have earlier onset of the disease and more severe symptoms; andWHEREAS, Scleroderma commonly occurs between 25 and 55 years of age; andWHEREAS, Symptoms commonly affect the face, feet, fingers, and hands first, and early symptoms include hardening and tightening of the skin, swelling and itchiness; andWHEREAS, Diagnosis may include physical exams, laboratory tests for antibodies, skin biopsies, computerized tomography, echocardiograms and pulmonary function tests; andWHEREAS, There is not a cure for scleroderma, but treatment may include medications to dilate blood vessels, suppress the immune system, reduce stomach acid, prevent infections of ulcers caused by Raynaud's phenomenon and alleviate pain, in addition to physical and occupational therapies and stem cell and organ transplants; andWHEREAS, Symptoms associated with scleroderma may decrease on their own in three to six years, while systemic scleroderma, which damages the internal organs, continues to worsen; andWHEREAS, Thomas Jefferson University, the University of Pennsylvania, the University of Pittsburgh and other entities in Pennsylvania continue to research scleroderma, enabling individuals to receive treatment to mitigate their symptoms; andWHEREAS, Awareness of rare diseases such as scleroderma assists in individuals' knowledge about the symptoms, research to treat these rare diseases and providing supports to individuals with rare diseases; therefore be itRESOLVED, That the House of Representatives recognize the month of June 2025 as "Scleroderma Awareness Month" and June 29, 2025, as "World Scleroderma Day" in Pennsylvania.20250HR0182PN1280 - 2 - 123456789101112131415161718192021222324252627282930